|
Name |
alpha-Guaiene
|
Molecular Formula | C15H24 | |
IUPAC Name* |
(1S,4S,7R)-1,4-dimethyl-7-prop-1-en-2-yl-1,2,3,4,5,6,7,8-octahydroazulene
|
|
SMILES |
C[C@H]1CC[C@H](CC2=C1CC[C@@H]2C)C(=C)C
|
|
InChI |
InChI=1S/C15H24/c1-10(2)13-7-5-11(3)14-8-6-12(4)15(14)9-13/h11-13H,1,5-9H2,2-4H3/t11-,12-,13+/m0/s1
|
|
InChIKey |
ADIDQIZBYUABQK-RWMBFGLXSA-N
|
|
Synonyms |
alpha-Guaiene; Guaia-1(5),11-diene; 3691-12-1; (1S,4S,7R)-1,4-dimethyl-7-(prop-1-en-2-yl)-1,2,3,4,5,6,7,8-octahydroazulene; (1S,4S,7R)-1,4-dimethyl-7-prop-1-en-2-yl-1,2,3,4,5,6,7,8-octahydroazulene; Azulene, 1,2,3,4,5,6,7,8-octahydro-1,4-dimethyl-7-(1-methylethenyl)-, [1S-(1.alpha.,4.alpha.,7.alpha.)]-; DTXSID5052046; CHEBI:63443; 7-Isopropenyl-1,4-dimethyl-1,2,3,4,5,6,7,8-octahydroazulene-, [1S-(1.alpha.,4.alpha.,7.alpha.)]-; ZINC70454368; C20161; Q5613309
|
|
CAS | 3691-12-1 | |
PubChem CID | 5317844 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 204.35 | ALogp: | 4.6 |
HBD: | 0 | HBA: | 0 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 0.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 15 | QED Weighted: | 0.518 |
Caco-2 Permeability: | -4.584 | MDCK Permeability: | 0.00001520 |
Pgp-inhibitor: | 0.977 | Pgp-substrate: | 0.006 |
Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.931 |
30% Bioavailability (F30%): | 0.032 |
Blood-Brain-Barrier Penetration (BBB): | 0.416 | Plasma Protein Binding (PPB): | 95.06% |
Volume Distribution (VD): | 3.288 | Fu: | 2.73% |
CYP1A2-inhibitor: | 0.607 | CYP1A2-substrate: | 0.531 |
CYP2C19-inhibitor: | 0.297 | CYP2C19-substrate: | 0.571 |
CYP2C9-inhibitor: | 0.35 | CYP2C9-substrate: | 0.367 |
CYP2D6-inhibitor: | 0.119 | CYP2D6-substrate: | 0.833 |
CYP3A4-inhibitor: | 0.41 | CYP3A4-substrate: | 0.344 |
Clearance (CL): | 8.168 | Half-life (T1/2): | 0.095 |
hERG Blockers: | 0.021 | Human Hepatotoxicity (H-HT): | 0.093 |
Drug-inuced Liver Injury (DILI): | 0.594 | AMES Toxicity: | 0.022 |
Rat Oral Acute Toxicity: | 0.327 | Maximum Recommended Daily Dose: | 0.948 |
Skin Sensitization: | 0.095 | Carcinogencity: | 0.867 |
Eye Corrosion: | 0.548 | Eye Irritation: | 0.941 |
Respiratory Toxicity: | 0.918 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC000839 | 1.000 | D0I2SD | 0.225 | ||||
ENC001013 | 0.585 | D04SFH | 0.225 | ||||
ENC000567 | 0.489 | D0F1UL | 0.221 | ||||
ENC000808 | 0.464 | D07BSQ | 0.221 | ||||
ENC000787 | 0.390 | D0G8OC | 0.210 | ||||
ENC001295 | 0.390 | D04CSZ | 0.207 | ||||
ENC000411 | 0.373 | D0W3OS | 0.207 | ||||
ENC001832 | 0.367 | D0B4RU | 0.207 | ||||
ENC001829 | 0.344 | D0K0EK | 0.205 | ||||
ENC002219 | 0.333 | D0T7ZQ | 0.205 |